In vivo CAR-T Platform

About Alaya.bio

Alaya.bio is a private, preclinical biotech founded in 2021, focusing on nanoparticle-based delivery systems for next-generation CAR-T therapies. The company is developing a polymeric nanoparticle platform intended to overcome key limitations in current cell therapies, such as high cost, complex manufacturing, and poor efficacy in solid tumors, by enabling efficient in vivo genetic reprogramming of immune cells. With operations in Paris and Cambridge, MA, and led by a seasoned duo of biotech executives, the company is advancing its platform through key asset acquisitions and a collaboration with a leading global cancer center.

About Vyriad

Vyriad is a private, clinical-stage biotech developing a suite of targeted viral delivery platforms for genetic medicines and oncolytic virotherapy. Founded by Mayo Clinic scientists, the company leverages deep expertise in viral engineering, particularly with vesicular stomatitis virus (VSV) and measles virus backbones, to create therapies that directly target cells in the body. With active clinical trials in oncology and a partnership-driven business model, Vyriad aims to de-risk and advance novel treatments from preclinical development through manufacturing and early-phase clinical testing.

Therapeutic Areas

Other Oncology (unspecified) Drugs